ARTICLE SCORE:
INCLUSION CRITERIA:
1. The study was a prospective,
randomized controlled trial.
2. The study was a prospective cohort with
a control group, not randomized.
3. The study was a retrospective case
control study or cohort study with a control group, or a prospective
cohort study without a control group or a retrospective case
series.
4. There was significantly greater
frequency of thrombocytopenia in patients treated compared to patients not
treated with the suspected drug.
REASON FOR EXCLUSION:
1. Insufficient clinical data with
which to evaluate the relationship between drug administration and thrombocytopenia
2. Platelet count of 100,000 cells/mL
or more
3. Agents
that cause thrombocytopenia due to marrow suppression (i.e. chemotherapy,
valproate, linezolid, penicillamine)
4. Agents
that cause thrombocytopenia due to accelerated clearance of platelets (i.e.
porcine factor VIII or Desmopressin in patients with
2B VWD)
5. Agents
that cause sustained TCP without marrow suppression (possible ITP; i.e. MMR,
G-CSF, Alemtuzumab)
6. Patient
exposed to nontherapeutic agent or experimental agent or used an agent in a
nontherapeutic manner
7. Drug-induced
disease includes things other than thrombocytopenia
8. Neonatal thrombocytopenia that was
attributed to a drug taken by the mother